SeqOnce Biosciences Secures Series Seed Financing

FOR IMMEDIATE RELEASE:

May 8, 2018

Contact:

Chris Angermayer, CEO
(626) 460- 3050
chris@seqonce.com

Investment capital will enable SeqOnce to launch its Library Construction Kit for Next Generation Sequencing

PASADENA, Calif. (May 7, 2018) – SeqOnce Biosciences, Inc. announced today it has completed a

$1 million series seed capital funding round led by Pasadena, California based Mount Wilson Ventures (MWV). The funds will be deployed to support the commercialization of SeqOnce’s fast and simple library construction kit for whole genome next generation sequencing (NGS).

“SeqOnce has developed a remarkably fast and efficient protocol for library preparation that will disrupt the growing NGS market,” said Mike Giardello, Ph.D., Partner at Mount Wilson Ventures. “The SeqOnce kit reduces library construction time from a multi-hour process to sub-45 minutes, while producing consistently excellent results across a wide range of sample types and inputs. We are excited to provide SeqOnce the capital to scale up its operations and develop new products.”

Joseph Dunham, Ph.D., SeqOnce co-founder and Chief Science Officer, developed the proprietary chemistry that enables the preparation of samples for sequencing in less than 25% of the time required by most other library preparation methods. SeqOnce’s kit features a single-tube 3-step highly efficient protocol, including fragmentation. The technology can be applied to DNA from any sample source and can be adapted to most sequencing applications.

“With extensive knowledge and expansive vision, Mount Wilson Ventures is the perfect partner,” said Chris Angermayer, CEO of SeqOnce. “The funds raised will enable SeqOnce to commercially launch our first product and lay the foundation for the future growth and new products.”

In conjunction with the financing, Mike Giardello will join the Board of Directors of SeqOnce Biosciences. Dr. Giardello has been an active founder and manager of, and investor in, early-stage startups based in the physical sciences since completing his postdoc at Caltech in 1995.

About SeqOnce Biosciences, Inc.

SeqOnce Biosciences is a life science company developing innovative products for Next Generation Sequencing (NGS) that addresses critical needs in the research and clinical markets. Additional technologies for NGS library construction applications are currently in various stages of research and development. Learn more at http://www.seqonce.com.

About Mount Wilson Ventures

Mount Wilson Ventures is an early-stage venture fund that focuses on physical science, data science and workflow/platform technologies. MWV works side-by-side with founding teams to transition bench-proven technologies into viable products in a time and capital efficient way. Learn more at http://www.mountwilsonvc.com.